Financials

  • Market Capitalization 11.28 B
  • Employee 20 K
  • Founded N/A
  • CEO James C. Foster
  • Website www.criver.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BG5BL8
  • Industry Diagnostics & Research
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-69.81
Price to sales ratio
2.51

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
780
ICLR
ICON plc - Ordinary Shares
167.92 USD+0.12%-1.82%+13.73%+12.79%12.86 B USD
796
RVTY
Revvity, Inc. Common Stock
112.16 USD-0.12%+0.22%+8.26%+18.24%12.51 B USD
974
QGEN
Qiagen N.V. Common Shares
41.81 USD+0.70%+6.88%+13.09%-12.62%9.07 B USD
1242
BLLN
BillionToOne, Inc. - Class A common stock
125.78 USD-0.78%+1.44%+24.45%+25.78%5.79 B USD

Frequently asked questions about Charles River Laboratories International, Inc. Common Stock

What is the Charles River Laboratories International, Inc. Common Stock stock price today?

The current price of Charles River Laboratories International, Inc. Common Stock (CRL) is 234.16. Over the past 24 hours, the stock has changed by +0.31%. Follow the CRL chart for real-time price dynamics.

What is the stock ticker of Charles River Laboratories International, Inc. Common Stock?

Charles River Laboratories International, Inc. Common Stock trades under the ticker CRL. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Charles River Laboratories International, Inc. Common Stock stock going up?

CRL has changed by +1.22% over the last week, +26.10% over the last month, and +18.95% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was Charles River Laboratories International, Inc. Common Stock net income for the last quarter?

Charles River Laboratories International, Inc. Common Stock reported net income of -14.84 M for the last quarter. The previous quarter showed -276.56 M, which means net income changed by +94.63%.

How many employees does Charles River Laboratories International, Inc. Common Stock have?

As of the latest available data, Charles River Laboratories International, Inc. Common Stock has 19.7 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Charles River Laboratories International, Inc. Common Stock EBITDA?

Charles River Laboratories International, Inc. Common Stock EBITDA is 771.95 M, and its EBITDA margin is 77.52%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Charles River Laboratories International, Inc. Common Stock stock?

You can buy Charles River Laboratories International, Inc. Common Stock (CRL) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Charles River Laboratories International, Inc. Common Stock stock?

Investing in Charles River Laboratories International, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CRL chart and related analysis on metatrader.com as part of your research.

Charles River Laboratories International, Inc. Common Stock

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

News